Index No
|
Chemical Name
|
EC No
|
CAS No
|
Classification
|
Labelling
|
Specific Conc. Limits, M- factors and ATE
|
Notes
|
Hazard Class and Category Code(s)
|
Hazard statement Code(s)
|
Pictogram, Signal Word Code(s)
|
Hazard statement Code(s)
|
Suppl. Hazard statement Code(s)
|
‘005-007-00-2
|
boric acid [1]
boric acid [2]
|
233-139-2 [1]
234-343-4 [2]
|
10043-35-3 [1]
11113-50-1 [2]
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD’
|
|
|
|
‘005-008-00-8
|
diboron trioxide
|
215-125-8
|
1303-86-2
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD’
|
|
|
|
‘005-011-00-4
|
tetraboron disodium heptaoxide, hydrate; [1]
disodium tetraborate, anhydrous; [2]
orthoboric acid, sodium salt [3]
disodium tetraborate decahydrate [4]
disodium tetraborate pentahydrate [5]
|
235-541-3 [1]
215-540-4 [2]
237-560-2 [3]
215-540-4 [4]
215-540-4 [5]
|
12267-73-1 [1]
1330-43-4 [2]
13840-56-7 [3]
1303-96-4 [4]
12179-04-3 [5]
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD’
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
‘006-069-00-3
|
thiophanate-methyl (ISO);
dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate;
dimethyl 4,4′-(o-phenylene)bis(3-thioallophanate)
|
245-740-7
|
23564-05-8
|
Carc. 2
Muta. 2
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H351
H341
H332
H317
H400
H410
|
GHS08
GHS07
GHS09
Wng
|
H351
H341
H332
H317
H410
|
|
inhalation: ATE = 1,7 mg/l
(dusts and mists)
M = 10
M = 10’
|
|
‘006-076-00-1
|
mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt
|
-
|
8018-01-7
|
Carc. 2
Repr. 1B
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H351
H360D
H373 (thyroid, nervous system)
H317
H400
H410
|
GHS08
GHS07
GHS09
Dgr
|
H351
H360D
H373 (thyroid, nervous system)
H317
H410
|
|
M = 10
M = 10’
|
|
‘015-113-00-0
|
tolclofos-methyl (ISO);
O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate
|
260-515-3
|
57018-04-9
|
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
|
H317
H400
H410
|
GHS07
GHS09
Wng
|
H317
H410
|
|
M = 1
M = 1’
|
|
‘028-007-00-4
|
trinickel disulfide;
nickel subsulfide; [1]
heazlewoodite [2]
|
234-829-6 [1]
- [2]
|
12035-72-2 [1]
12035-71-1 [2]
|
Carc. 1A
Muta. 2
Acute Tox. 3
STOT RE 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H350i
H341
H331
H372**
H317
H400
H410
|
GHS08
GHS06
GHS09
Dgr
|
H350i
H341
H331
H372**
H317
H410
|
|
inhalation:
ATE = 0,92 mg/l
(dusts or mists)’
|
|
‘029-002-00-X
|
dicopper oxide;
copper (I) oxide
|
215-270-7
|
1317-39-1
|
Acute Tox. 4
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H332
H302
H318
H400
H410
|
GHS07
GHS05
GHS09
Dgr
|
H332
H302
H318
H410
|
|
inhalation: ATE = 3,34 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 100
M = 10’
|
|
‘029-015-00-0
|
copper thiocyanate
|
214-183-1
|
1111-67-7
|
Aquatic Acute 1
Aquatic Chronic 1
|
H400
H410
|
GHS09
Wng
|
H410
|
EUH032
|
M = 10
M = 10’
|
|
‘029-016-00-6
|
copper(II) oxide
|
215-269-1
|
1317-38-0
|
Aquatic Acute 1
Aquatic Chronic 1
|
H400
H410
|
GHS09
Wng
|
H410
|
|
M = 100
M = 10’
|
|
‘029-017-00-1
|
dicopper chloride trihydroxide
|
215-572-9
|
1332-65-6
|
Acute Tox. 4
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
|
H332
H301
H400
H410
|
GHS06
GHS09
Dgr
|
H332
H301
H410
|
|
inhalation: ATE = 2,83 mg/l (dusts or mists)
oral: ATE = 299 mg/kg bw
M = 10
M = 10’
|
|
‘029-018-00-7
|
tetracopper hexahydroxide sulphate; [1]
tetracopper hexahydroxide sulphate hydrate [2]
|
215-582-3 [1]
215-582-3 [2]
|
1333-22-8 [1]
12527-76-3 [2]
|
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
|
H302
H400
H410
|
GHS07
GHS09
Wng
|
H302
H410
|
|
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
|
|
‘029-019-01-X
|
copper flakes (coated with aliphatic acid)
|
-
|
-
|
Acute Tox. 3
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H331
H302
H319
H400
H410
|
GHS06
GHS09
Dgr
|
H331
H302
H319
H410
|
|
inhalation: ATE = 0,733 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
|
|
‘029-020-00-8
|
copper(II) carbonate—copper(II) hydroxide (1:1)
|
235-113-6
|
12069-69-1
|
Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H332
H302
H319
H400
H410
|
GHS07
GHS09
Wng
|
H332
H302
H319
H410
|
|
inhalation: ATE = 1,2 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
|
|
‘029-021-00-3
|
copper dihydroxide;
copper(II) hydroxide
|
243-815-9
|
20427-59-2
|
Acute Tox. 2
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H330
H302
H318
H400
H410
|
GHS06
GHS05
GHS09
Dgr
|
H330
H302
H318
H410
|
|
inhalation: ATE = 0,47 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
|
|
‘029-022-00-9
|
bordeaux mixture;
reaction products of copper sulphate with calcium dihydroxide
|
-
|
8011-63-0
|
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H332
H318
H400
H410
|
GHS07
GHS05
GHS09
Dgr
|
H332
H318
H410
|
|
inhalation: ATE = 1,97 mg/l (dusts or mists)
M = 10
M = 1’
|
|
‘029-023-00-4
|
copper sulphate pentahydrate
|
231-847-6
|
7758-99-8
|
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H302
H318
H400
H410
|
GHS07
GHS05
GHS09
Dgr
|
H302
H318
H410
|
|
oral: ATE = 481 mg/kg bw
M = 10
M = 1’
|
|
‘601-029-00-7
|
dipentene;
limonene [1]
(S)-p-mentha-1,8-diene; l-limonene [2]
trans-1-methyl-4-(1-methylvinyl)cyclohexene; [3]
(±)-1-methyl-4-(1-methylvinyl)cyclohexene [4]
|
205-341-0 [1]
227-815-6 [2]
229-977-3 [3]
231-732-0 [4]
|
138-86-3 [1]
5989-54-8 [2]
6876-12-6 [3]
7705-14-8 [4]
|
Flam. Liq. 3
Skin Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H226
H315
H317
H400
H410
|
GHS02
GHS07
GHS09
Wng
|
H226
H315
H317
H410
|
|
|
C’
|
‘601-096-00-2
|
(R)-p-mentha-1,8-diene;
d-limonene
|
227-813-5
|
5989-27-5
|
Flam. Liq. 3
Skin Irrit. 2
Skin Sens. 1B
Asp. Tox. 1
Aquatic Acute 1
Aquatic Chronic 3
|
H226
H315
H317
H304
H400
H412
|
GHS02
GHS07
GHS08
GHS09
Dgr
|
H226
H315
H317
H304
H410
|
|
M = 1’
|
|
‘603-024-00-5
|
1,4-dioxane
|
204-661-8
|
123-91-1
|
Flam. Liq. 2
Carc. 1B
STOT SE 3
Eye Irrit. 2
|
H225
H350
H335
H319
|
GHS02
GHS08
GHS07
Dgr
|
H225
H350
H335
H319
|
EUH019
EUH066
|
|
D’
|
‘603-066-00-4
|
7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide
|
203-437-7
|
106-87-6
|
Carc. 1B
Muta. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4
|
H350
H341
H360F
H331
H302
|
GHS08
GHS06
Dgr
|
H350
H341
H360F
H331
H302
|
|
inhalation: ATE = 0,5 mg/l (dusts or mists)
oral: ATE = 1 847 mg/kg bw’
|
|
‘603-098-00-9
|
2-phenoxyethanol
|
204-589-7
|
122-99-6
|
Acute Tox. 4
STOT SE 3
Eye Dam. 1
|
H302
H335
H318
|
GHS05
GHS07
Dgr
|
H302
H335
H318
|
|
oral:
ATE = 1 394 mg/kg bw’
|
|
‘606-004-00-4
|
4-methylpentan-2-one; isobutyl methyl ketone
|
203-550-1
|
108-10-1
|
Flam. Liq. 2
Carc. 2
Acute Tox. 4
STOT SE 3
Eye Irrit. 2
|
H225
H351
H332
H336
H319
|
GHS02
GHS07
GHS08
Dgr
|
H225
H351
H332
H336
H319
|
EUH066
|
inhalation: ATE = 11 mg/l (vapours)’
|
|
‘607-421-00-4
|
cypermethrin (ISO);
α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60
|
257-842-9
|
52315-07-8
|
Acute Tox. 4
Acute Tox. 4
STOT SE 3
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
|
H332
H302
H335
H373 (nervous system)
H400
H410
|
GHS07
GHS08
GHS09
Wng
|
H332
H302
H335
H373 (nervous system)
H410
|
|
oral; ATE = 500 mg/kg bw
inhalation; ATE = 3,3 mg/l (dusts or mists)
M = 100000
M = 100000’
|
|
‘607-424-00-0
|
trifloxystrobin (ISO); methyl (E)-methoxyimino-{(E)-α-[1-(α,α,α-trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl}acetate
|
-
|
141517-21-7
|
Lact.
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H362
H317
H400
H410
|
GHS07
GHS09
Wng
|
H362
H317
H410
|
|
M = 100
M = 10’
|
|
‘607-434-00-5
|
mecoprop-P (ISO) [1] and its salts;
(R)-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts
|
240-539-0 [1]
|
16484-77-8 [1]
|
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H302
H318
H400
H410
|
GHS07
GHS05
GHS09
Dgr
|
H302
H318
H410
|
|
oral: ATE = 431 mg/kg bw
M = 10
M = 10’
|
|
‘608-058-00-4
|
esfenvalerate (ISO);
(S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate
|
-
|
66230-04-4
|
Acute Tox. 3
Acute Tox. 3
STOT SE 1
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H331
H301
H370 (nervous system)
H373
H317
H400
H410
|
GHS06
GHS08
GHS09
Dgr
|
H331
H301
H370 (nervous system)
H373
H317
H410
|
|
oral; ATE = 88,5 mg/kg bw
inhalation; ATE = 0,53 mg/l (dusts or mists)
M = 10 000
M = 10 000 ’
|
|
‘612-067-00-9
|
3-aminomethyl-3,5,5-trimethylcyclohexylamine
|
220-666-8
|
2855-13-2
|
Acute Tox. 4
Skin Corr. 1B
Eye Dam. 1
Skin Sens. 1A
|
H302
H314
H318
H317
|
GHS05
GHS07
Dgr
|
H302
H314
H317
|
|
oral: ATE = 1 030 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,001 %’
|
|
‘612-252-00-4
|
imidacloprid (ISO);
(E)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine;
(2E)-1-[(6-chloropyridin-3-yl) methyl]-N-nitroimidazolidin-2-imine
|
428-040-8
|
138261-41-3
|
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
|
H301
H400
H410
|
GHS06
GHS09
Dgr
|
H301
H410
|
|
oral: ATE = 131 mg/kg bw
M = 100
M = 1 000 ’
|
|
‘613-048-00-8
|
carbendazim (ISO); methyl benzimidazol-2-ylcarbamate
|
234-232-0
|
10605-21-7
|
Muta. 1B
Repr. 1B
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H340
H360FD
H317
H400
H410
|
GHS07
GHS08
GHS09
Dgr
|
H340
H360FD
H317
H410
|
|
M = 10
M = 10’
|
|
‘613-102-00-0
|
dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine
|
404-200-2
|
110488-70-5
|
Repr. 1B
Aquatic Chronic 2
|
H360F
H411
|
GHS08
GHS09
Dgr
|
H360F
H411’
|
|
|
|
‘613-111-00-X
|
1,2,4-triazole
|
206-022-9
|
288-88-0
|
Repr. 1B
Acute Tox. 4
Eye Irrit. 2
|
H360FD
H302
H319
|
GHS08
GHS07
Dgr
|
H360FD
H302
H319
|
|
oral: ATE = 1 320 mg/kg bw’
|
|
‘613-166-00-X
|
flumioxazin (ISO);
N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide
|
-
|
103361-09-7
|
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H361d
H400
H410
|
GHS08
GHS09
Wng
|
H361d
H410
|
|
M = 1 000
M = 1 000 ’
|
|
‘613-208-00-7
|
imazamox (ISO);
(RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid
|
-
|
114311-32-9
|
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H361d
H400
H410
|
GHS08
GHS09
Wng
|
H361d
H410
|
|
M = 10
M = 10’
|
|
‘613-267-00-9
|
thiamethoxam (ISO);
3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine
|
428-650-4
|
153719-23-4
|
Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
|
H361fd
H302
H400
H410
|
GHS07
GHS08
GHS09
Wng
|
H361fd
H302
H410
|
|
oral: ATE = 780 mg/kg bw
M = 10
M = 10’
|
|
‘613-282-00-0
|
triticonazole (ISO);
(RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol
|
-
|
138182-18-0
|
Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
|
H361f
H373
H400
H410
|
GHS08
GHS09
Wng
|
H361f
H373
H410
|
|
M = 1
M = 1’
|
|
‘616-032-00-9
|
diflufenican (ISO);
N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro-m-tolyloxy) nicotinanilide
|
-
|
83164-33-4
|
Aquatic Acute 1
Aquatic Chronic 1
|
H400
H410
|
GHS09
Wng
|
H410
|
|
M = 10 000
M = 1 000 ’
|
|
‘616-106-00-0
|
phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate
|
237-199-0
|
13684-63-4
|
Aquatic Acute 1
Aquatic Chronic 1
|
H400
H410
|
GHS09
Wng
|
H410
|
|
M = 10
M = 10’
|
|
‘616-113-00-9
|
desmedipham (ISO);
ethyl 3-phenylcarbamoyloxyphenylcarbamate
|
237-198-5
|
13684-56-5
|
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H361d
H400
H410
|
GHS08
GHS09
Wng
|
H361d
H410
|
|
M = 10
M = 10’
|
|